Treatment redirection from cure to palliation, then cure again?-a cautious, but urgent matter

Affiliations

Editorial

Jhingook Kim. Transl Lung Cancer Res. 2018 Feb.

. 2018 Feb;7(Suppl 1):S5-S8.

doi: 10.21037/tlcr.2017.11.06.

¹ Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is 'cured' from postoperative recurrence?
Sekihara K, Hishida T, Yoshida J, Oki T, Omori T, Katsumata S, Ueda T, Miyoshi T, Goto M, Nakasone S, Ichikawa T, Matsuzawa R, Aokage K, Goto K, Tsuboi M. Sekihara K, et al. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):522-528. doi: 10.1093/ejcts/ezx127. Eur J Cardiothorac Surg. 2017. PMID: 28482033

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. 10.1056/NEJMoa1214886 - DOI - PubMed
1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
1. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-6. 10.1136/thx.2007.094912 - DOI - PubMed
1. Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax 2010;65:241-5. 10.1136/thx.2008.110825 - DOI - PubMed